Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 2,700 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,700 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $20.04, for a total value of $54,108.00. Following the completion of the transaction, the insider now directly owns 160,888 shares of the company’s stock, valued at approximately $3,224,195.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, November 11th, Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock. The stock was sold at an average price of $20.01, for a total value of $28,194.09.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Price Performance

TRDA stock opened at $19.96 on Thursday. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $20.49. The company has a market capitalization of $746.90 million, a price-to-earnings ratio of 12.55 and a beta of -0.26. The business has a 50 day simple moving average of $16.62 and a two-hundred day simple moving average of $15.85.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Sell-side analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TRDA has been the subject of a number of recent research reports. HC Wainwright boosted their price target on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Oppenheimer boosted their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TRDA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after acquiring an additional 3,644 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Entrada Therapeutics by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after acquiring an additional 23,643 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Entrada Therapeutics during the 3rd quarter valued at approximately $1,109,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Entrada Therapeutics by 132.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock valued at $2,215,000 after acquiring an additional 78,953 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in shares of Entrada Therapeutics by 71.8% during the 3rd quarter. GSA Capital Partners LLP now owns 36,577 shares of the company’s stock valued at $585,000 after acquiring an additional 15,284 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.